Clinical Trial Update: A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) [Phase 3]

View source ↗

Summary

A Phase 3 study comparing KSI-301 with aflibercept in macular edema due to retinal vein occlusion has completed. Results were posted in June 2024 evaluating eff…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema
• Retinal Vein Occlusion

Drugs mentioned

• Aflibercept (Aflibercept)
• KSI-301 (KSI-301)

Snippet

Sponsor: Kodiak Sciences Inc | Conditions: Macular Edema, Retinal Vein Occlusion | Phase 3 | Status: COMPLETED | Results posted: 2024-06-06